Welcome to our dedicated page for Heartbeam news (Ticker: BEAT), a resource for investors and traders seeking the latest updates and insights on Heartbeam stock.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company that regularly issues updates on its cardiac monitoring platform, regulatory milestones, and commercialization plans. Company news highlights its focus on transforming cardiac care through portable, cable-free ECG technologies that can be used by adult patients in clinical settings or at home for arrhythmia assessment.
News releases frequently cover developments related to HeartBeam’s 3D ECG technology and 12-lead ECG synthesis software. These include FDA 510(k) clearance for arrhythmia assessment, the regulatory path for the 12-lead synthesis software, and the company’s responses to a Not Substantially Equivalent (NSE) decision and subsequent successful appeal. Investors can also find updates on clinical studies such as the VALID-ECG study and deep learning research presented at conferences like HRX Live, which examine how HeartBeam’s algorithms perform in detecting atrial fibrillation, atrial flutter, and sinus rhythm.
HeartBeam’s news flow also addresses commercial readiness, including plans for limited U.S. launch with concierge and preventive cardiology practices, establishment of a cardiology reader service, and infrastructure for customer service, contract manufacturing, and logistics. Announcements about the partnership with HeartNexus, Inc. describe how synthesized 12-lead ECGs from HeartBeam’s system will be reviewed by a network of board-certified cardiologists, supporting arrhythmia assessment and patient triage outside traditional healthcare facilities.
In addition, periodic earnings releases and conference participation notices provide insight into the company’s operating expenses, cash position, and engagement with investors and industry partners. Visitors to this news page can review these updates to understand how HeartBeam is progressing on regulatory, clinical, and commercialization objectives for its cardiac monitoring technologies.
HeartBeam (NASDAQ: BEAT) closed an underwritten public offering on April 16, 2026 of 12,500,000 shares for $10.0 million gross proceeds. The offering was led by ClearCardio, company leadership, board members, existing investors, and institutional participants.
Net proceeds are intended to support commercialization of its FDA-cleared 12-lead synthesized ECG system, advance an extended-wear patch and heart attack detection work, enhance AI capabilities, and for working capital and general corporate purposes. Titan Partners acted as sole bookrunner; the offering was made under a Form S-3/A shelf registration (File No. 333-293307).
HeartBeam (NASDAQ: BEAT) priced an underwritten public offering of 12,500,000 shares for gross proceeds of $10.0 million, with a 30-day overallotment option for up to 1,875,000 additional shares. The offering is expected to close on or about April 16, 2026.
Proceeds are intended to support commercialization of HeartBeam's FDA-cleared 12-lead synthesized ECG, advance an extended-wear patch and heart-attack detection work, enhance AI capabilities, and for working capital and general corporate purposes.
HeartBeam (NASDAQ: BEAT) announced it is commencing an underwritten public offering of common stock on April 14, 2026. The company said proceeds are intended to advance commercialization of its FDA-cleared 12-lead synthesized ECG system, develop an extended-wear patch and heart attack detection, enhance AI capabilities, and fund general corporate purposes.
The offering is being made from a shelf registration declared effective March 17, 2026, with Titan Partners as sole bookrunner; terms, size, and timing remain subject to market conditions.
HeartBeam (NASDAQ: BEAT) reported Q4 and full-year 2025 results and commercial progress. Key milestones include FDA 510(k) clearance (Dec 2025) for a cable-free synthesized 12-lead ECG, a first commercial partnership with ClearCardio, enrollment in the ALIGN-ACS pilot, and a working prototype of a 12-lead extended-wear ECG patch.
Financials: cash $4.4M at Dec 31, 2025; Q4 net loss $5.3M; full-year net loss $21.0M; R&D 2025 $13.5M. Management hosted a webcast March 12, 2026.
HeartBeam (NASDAQ: BEAT) announced a strategic collaboration with the Icahn School of Medicine at Mount Sinai to co-develop and validate next‑generation AI‑ECG algorithms using HeartBeam’s 3D ECG platform.
The partnership aims to train AI on longitudinal, synthesized 12‑lead ECGs captured at home to enable personalized, clinically relevant cardiac assessments and expand clinical indications and reimbursement pathways.
HeartBeam (NASDAQ: BEAT) said management will attend investor and industry conferences in March 2026 to provide commercial-launch updates and product demonstrations.
Key events: Oppenheimer MedTech & Services (virtual) March 16-17 with a March 16 webcast; ROTH Conference (Dana Point) March 23-24; ACC.26 (New Orleans) March 28-30 with booth #209. The FDA-cleared HeartBeam System will be demoed and a working 12-lead ECG extended wear patch prototype (not FDA-approved) will be shown to physicians and partners.
HeartBeam (NASDAQ: BEAT) announced first patient enrollments in the ALIGN-ACS pilot study for heart attack detection on March 5, 2026. The study will compare HeartBeam’s 3D ECG device with standard 12-lead ECGs in ER chest-pain patients to inform a multicenter pivotal study and potential FDA indication expansion.
The pilot aims to enroll 100 ER chest-pain patients, build on prior 3D ECG proof-of-concept results, and accelerate symptom-to-door assessment by enabling clinical-grade ECG capture outside hospitals.
HeartBeam (NASDAQ: BEAT) will host a conference call on Thursday, March 12, 2026 at 4:30 p.m. Eastern to discuss fourth-quarter and full-year 2025 results and strategic updates on the 12-lead ECG extended wear patch. A presentation and short video will accompany the webcast and will be available afterward in investor relations.
HeartBeam (NASDAQ: BEAT) announced its first commercial customer: ClearCardio, a preventive cardiology practice that will integrate HeartBeam’s synthesized 12-lead ECG technology into its member prevention programs.
The agreement is an initial staged rollout under a Letter of Intent, includes a planned ClearCardio investment, targets replication across concierge and executive health networks, and references a structured direct-pay segment representing 5 million patients.
HeartBeam (NASDAQ: BEAT) appointed Bryan Humbarger as Chief Commercial Officer, effective January 22, 2026. Humbarger brings more than 25 years of commercial leadership in cardiovascular and MedTech firms and will lead the company’s commercialization for its recently FDA-cleared 12-lead ECG system for arrhythmia assessment. His remit includes directing a limited launch, developing partnerships with channel partners and cardiology practices, validating real-world performance through reference sites, and advancing initiatives for heart attack detection and a 12-lead extended-wear ECG patch.
This role is newly created to scale commercial strategy and execute initial market introduction while building sales and clinical support infrastructure.